A critical assessment of new therapies in inflammatory bowel disease.

A critical assessment of new therapies in inflammatory bowel disease.

Item
http://www.wikidata.org/entity/Q34631399
Exploitation of the nicotinic anti-inflammatory pathway for the treatment of epithelial inflammatory diseases.Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis.Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition.Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults.Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series.Piperine Suppresses the Expression of CXCL8 in Lipopolysaccharide-Activated SW480 and HT-29 Cells via Downregulating the Mitogen-Activated Protein Kinase Pathways.Severe polyneuropathy complicating active Crohn's disease: rapid response to Infliximab.Natalizumab: a promising treatment for Crohn's disease.Varicella-like generalized pustulosis induced by adalimumab.Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis.[Clinical experience with the use of infliximab in 44 patients with Crohn's disease].
P2860

A critical assessment of new therapies in inflammatory bowel disease.

Item
http://www.wikidata.org/entity/Q34631399
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A critical assessment of new therapies in inflammatory bowel disease.
@ast
A critical assessment of new therapies in inflammatory bowel disease.
@en
A critical assessment of new therapies in inflammatory bowel disease.
@nl
type
label
A critical assessment of new therapies in inflammatory bowel disease.
@ast
A critical assessment of new therapies in inflammatory bowel disease.
@en
A critical assessment of new therapies in inflammatory bowel disease.
@nl
prefLabel
A critical assessment of new therapies in inflammatory bowel disease.
@ast
A critical assessment of new therapies in inflammatory bowel disease.
@en
A critical assessment of new therapies in inflammatory bowel disease.
@nl
P1433
P1476
P2860
P304
P31
P356
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
A critical assessment of new therapies in inflammatory bowel disease.
@en
P2860
P304
P31
P356
10.1046/J.1440-1746.17.S1.1.X
P478
P50
P577
P5875
P698
P921